Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Albuvirtide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    2ndLine Albuvirtide Based 2-Drug Regimen Non-Inferior to 3-Drug Standard Therapy
    2ndLine Albuvirtide Based 2-Drug Regimen Non-Inferior to 3-Drug Standard Therapy

    19 Jul 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/ru/press-releases/frontier-biotechnologies-first-long-acting-injectable-aikening-r-in-a-two-drug-regimen-for-hiv-proves-safe-and-efficacious-for-patients-813835556.html

    PRNEWSWIRE
    19 Jul 2021
    Share Share
    Frontier's HIV Drug Approved In China
    Frontier's HIV Drug Approved In China

    06 Jun 2018

    // Jaime De Leon BIOCENTURY

    https://www.biocentury.com/bc-extra/company-news/2018-06-05/frontiers-hiv-drug-approved-china

    Jaime De Leon BIOCENTURY
    06 Jun 2018
    Share Share
    “Patient-Centricity”or “Pay-Per-Results” Is a Hot Topic
    “Patient-Centricity”or “Pay-Per-Results” Is a Hot Topic

    06 Jun 2018

    // Mark Terry BIOSPACE

    https://www.biospace.com/article/-patient-centricity-or-pay-per-results-is-a-hot-topic-at-bio-2018/

    Mark Terry BIOSPACE
    06 Jun 2018
    Share Share
    CFDA approves domestically developed anti-HIV drug
    CFDA approves domestically developed anti-HIV drug

    06 Jun 2018

    // BIOSPECTRUM

    https://www.biospectrumasia.com/news/30/11047/cfda-approves-domestically-developed-anti-hiv-drug.html

    BIOSPECTRUM
    06 Jun 2018
    Share Share